COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

8.365 +0.735 (+9.63%)

Streaming Delayed Price Updated: 1:10 PM EST, Feb 18, 2026 Add to My Watchlist

Price and Volume

Volume	5,971,183
Open	8.260
Bid (Size)	8.360 (400)
Ask (Size)	8.370 (200)
Prev. Close	7.630
Today's Range	7.940 - 8.900
52wk Range	2.250 - 8.795
Shares Outstanding	41,695,335
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗

Today 4:03 EST

The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter.

Via Stocktwits

Compass Pathways Launches Proposed $150.0 Million Public Offering

February 17, 2026

From Compass Pathfinder Limited

Via Business Wire

Performance

YTD	+27.7%	+27.7%
1 Month	+14.4%	+14.4%
3 Month	+55.2%	+55.2%
6 Month	+104.5%	+104.5%
1 Year	+88.8%	+88.8%

More News

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 17, 2026

Via Chartmill

Why Did Compass Pathways Stock Rocket Higher Today? ↗

February 17, 2026

Via The Motley Fool

CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗

January 07, 2026

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

February 17, 2026

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

February 17, 2026

Via Chartmill

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

February 17, 2026

From Compass Pathfinder Limited

Via Business Wire

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗

February 17, 2026

Via Stocktwits

CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗

February 17, 2026

Via Stocktwits

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

February 16, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

January 07, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

January 06, 2026

From Compass Pathfinder Limited

Via Business Wire

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗

December 24, 2025

Via Stocktwits

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

December 09, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Two Investor Conferences in December

November 20, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

November 05, 2025

From Compass Pathfinder Limited

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

November 04, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

October 29, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

October 28, 2025

From Compass Pathfinder Limited

Via Business Wire

Design Therapeutics Appoints Justin Gover to Board of Directors

September 10, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

September 02, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Four Investor Conferences in September

August 27, 2025

From Compass Pathfinder Limited

Via Business Wire

Frequently Asked Questions

Is COMPASS Pathways Plc - American Depository Shares publicly traded?

Yes, COMPASS Pathways Plc - American Depository Shares is publicly traded.

What exchange does COMPASS Pathways Plc - American Depository Shares trade on?

COMPASS Pathways Plc - American Depository Shares trades on the Nasdaq Stock Market

What is the ticker symbol for COMPASS Pathways Plc - American Depository Shares?

The ticker symbol for COMPASS Pathways Plc - American Depository Shares is CMPS on the Nasdaq Stock Market

What is the current price of COMPASS Pathways Plc - American Depository Shares?

The current price of COMPASS Pathways Plc - American Depository Shares is 8.365

When was COMPASS Pathways Plc - American Depository Shares last traded?

The last trade of COMPASS Pathways Plc - American Depository Shares was at 02/18/26 01:10 PM ET

What is the market capitalization of COMPASS Pathways Plc - American Depository Shares?

The market capitalization of COMPASS Pathways Plc - American Depository Shares is 348.78M

How many shares of COMPASS Pathways Plc - American Depository Shares are outstanding?

COMPASS Pathways Plc - American Depository Shares has 349M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.